CWBR Soars Over 30%, VCEL Lifts Revenue Outlook, ZIOP On Watch

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. CohBar Inc. (CWBR)

Gained 34.33% to close Tuesday's (Aug 7) trading at $6.32.

News: No news

Clinical Trials:

The lead drug candidate is CB4211, for nonalcoholic steatohepatitis (NASH) and obesity. The Company initiated a Phase 1a/1b clinical trial of CB4211 as recently as last month.

Recent events:

-- On June 25, the Company was added to the US small-cap Russell 2000 Index during the 2018 Russell indexes reconstitution. -- On June 7, 2018, the Company announced the appointment of Philippe Calais to its Board of Directors, and to the Board's Audit Committee. -- On December 15, 2017, CohBar's common stock was uplisted to the NASDAQ Capital Market from the OTCQX Best Marketplace.

Near-term Catalyst:

The Company is scheduled to release its second quarter 2018 financial results on Tuesday, August 14, 2018.

2. Vericel Corporation (VCEL)

Gained 25% to close Tuesday's trading at $12.75.

News: The Company has reported solid revenue growth in the second quarter of 2018 and boosted its outlook for the full year.

Total net revenues for the quarter ended June 30, 2018 were $19.0 million compared to $16.95 million in the year-earlier quarter.

On a GAAP basis, the net loss for the recent quarter widened to $4.7 million or $0.12 per share from $2.4 million or $0.07 per share in the year-ago quarter.

Looking ahead to full year 2018, the Company now expects total net product revenues to be in the range of $80 million to $83 million, up from its previous guidance of $73 million to $78 million.

3. Mallinckrodt Public Limited Company (MNK)

Gained 20.90% to close Tuesday's trading at $29.44.

News: The Company reported second quarter results, and raised its outlook for full year 2018.

Net sales were $631.7 million in the recent second quarter compared to $600.1 million in the year-ago quarter. Adjusted earnings per share were $1.78 in Q2, 2018 versus $1.36 in Q2, 2017.

Looking ahead to full year 2018, the Company now expects total net sales for continuing operations to increase 4% to 7% over last year compared to its earlier guidance of 3% to 6% growth. Net sales in 2017 were $3.222 billion.

The Company has also lifted its adjusted EPS guidance range for full year to $6.50 to $6.90 from its prior outlook range of $6.00 to $6.50. Adjusted earnings per share were $7.49 in 2017.

4. Tactile Systems Technology Inc. (TCMD)

Gained 18.20% to close Tuesday's trading at $57.66.

News: The Company reported Q2 results and increased its annual revenue guidance.

Net income for the second quarter of 2018 decreased to $2.6 million or $0.13 per share from $3.8 million or $0.20 per share in the second quarter of 2017. Total revenue for the recent second quarter increased 30% to $34.1 million from $26.3 million in the year-ago quarter.

Looking ahead, the Company now expects revenue in the range of $134 million to $135 million, representing growth of 23% to 24% year-over-year, compared to revenue of $109.3 million in 2017. This compares to the Company's prior guidance range of $132 million to $134 million.

5. ZIOPHARM Oncology Inc. (ZIOP)

Gained 17.70% to close Tuesday's trading at $2.66.

News: The Company has made changes to its Board of Directors.

Scott Tarriff, CEO of Eagle Pharmaceuticals has been elected Lead Director, succeeding Sir Murray Brennan, M.D.

Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018. Doug Pagán and Elan Ezickson have been nominated for election to the Board at the Company's annual meeting of stockholders, ZIOPHARM noted.

Near-term Catalyst:

The Company is slated to announce second quarter financial results on August 8, 2018.